Lead Sponsor

Allist Pharmaceuticals, Inc.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Written informed consent
•2. Advanced (metastatic or unresectable) KRAS p.G12C mutant solid tumors, with failure or absence of standard treatment
•3. Subject must be ≥18 years
•4. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
•5. Subjects with life expectancy ≥3 months.
•6. Subjects must have at least one measurable lesion as defined by RECIST v1.1.
•7. There was no serious organ dysfunction in the screening stage
•8. Male or female subjects of reproductive age agree to use adequate contraception

•1. History of intestinal disease or major gastric surgery or inability to swallow oral medications
•2. Other active cancer
•3. Previously treated with KRAS G12C inhibitor
•4. Active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV)
•5. Impaired heart function or clinically significant heart disease
•6. Pregnant or breast-feeding
•7. Previous allogeneic bone marrow transplant or organ transplant
•8. Intended study subjects who were unable to abstain from alcohol during medication
•9. Other unqualified conditions judged by the investigators

Related studies

NCT07589530 · Advanced Solid Tumors, Metastatic Solid Tumors, and more

NCT07042100 · Advanced Solid Tumors

NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation

NCT07087197 · Metastatic Solid Tumors

NCT07300150 · Colorectal Cancer, Pancreatic Cancer, and more

A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China